Vaksen kont Varisèl (Saranpyon):Sa Ou Dwe Konnen
During the COVID-19 health crisis, community pharmacists had an enhanced role in supporting health-care systems that were overburdened by managing seriously ill patients. This study was undertaken to determine the patterns of community supply of antiviral and antibacterial agents from community phar...macies during the COVID-19 pandemic in selected countries in eastern Europe and central Asia. Nine countries – Armenia, Georgia, Kazakhstan, Kyrgyzstan, North Macedonia, the Russian Federation, Serbia, Tajikistan and Uzbekistan – participated in this cross-sectional study.
more
WHO recently conducted a survey to assess the availability and cost of a national tracer list of essential medicines in the outpatient sector in Ukraine using a new collection tool – the WHO Essential Medicines and Health Products Price and Availability Monitoring Mobile Application. This tool fac...ilitates rapid and inexpensive data collection at the facility level.
more
Tuberculosis treatment failure results in increased risk of morbidity, drug resistance, transmission and mortality. There are few data about tuberculosis treatment outcomes in Burkina Faso. The current study investigated the factors associated with tuberculosis treatment failure in the central east ...health region of Burkina Faso.
more
This article examines the activities of national and international actors in Pharmaceutical Services (PS) in Mozambique from 2007 to 2012, focusing on the public provision of HIV/Aids, malaria and tuberculosis medicines. It describes how PS functions in the country, what actors are involved in this ...area and the relations among them, pursuing salient issues in the modus operandi of partners in cooperation.
more
Les conséquences néfastes de la mauvaise gestion et les faits de corruption dans le domaine de la
santé ont amené l’Organisation mondiale de la Santé (OMS) à mettre en place depuis 2004, un
programme de bonne gouvernance qui vise à améliorer les mesures de transparence dans
l’exercice... des fonctions du secteur pharmaceutique.
Notre pays, le Bénin, ayant souscrit à ce programme en 2007, l’OMS a commis des experts qui ont
procédé à l’évaluation des fonctions essentielles du secteur pharmaceutique public béninois.
De l’analyse des résultats de cette évaluation réalisée conformément aux normes admises par
l’OMS en la matière, il ressort qu’en République du Bénin, la gestion des produits
pharmaceutiques dans le secteur public présente une vulnérabilité modérée à la corruption.
Sur les six (06) fonctions ayant fait l’objet de l’évaluation, seule celle liée au contrôle de la
promotion des médicaments présente une forte vulnérabilité à la corruption en raison de la faible
note de 3,428 sur 10 dont elle a été créditée.
more
Journal des anthropologues n° 138-139, 2014
http://journals.openedition.org/jda/4444
Le médicament pharmaceutique industriel est un objet de santé
à la fois scientifique, populaire et marchand. Si ces deux premiers
caractères sont souvent mis en avant respectivement par les sciences
biom...édicales et pharmaceutiques, par la santé publique ainsi qu’à
travers les médias, sa troisième composante est plus souvent passée
sous silence. Elle tend à être dissimulée derrière ce qui est présenté
comme la vocation première du médicament, à savoir la santé des
individus, leur bien-être physique et psychique. Or, le caractère
marchand du médicament est un formidable vecteur de dynamiques
et d’initiatives. Il est peut-être ce qui explique avant tout
l’incroyable vitalité du secteur pharmaceutique de par la planète,
non sans poser de nombreux problèmes d’ordre sanitaire et de santé
publique.
more
Caring for burns patients from the incident scene to definitive treatment can be a complex, resource-consuming process with the potential to overwhelm health system capacity.This document provides practical guidance for building capacity and capability for burns care from clinical, human resources a...nd operational perspectives. It is therefore recommended that guidance in this document be applied to any contexts in which the local health system might struggle to cope and require surge support.
more
This report reviews and analyses the Affordable Medicines Programme, which was introduced in Ukraine in April 2017 to provide patients with improved access to 23 outpatient medicines for the treatment of chronic noncommunicable diseases. The evaluation combines both quantitative and qualitative anal...ysis. The findings confirm that the Programme has contributed to a significant increase in access to needed outpatient medicines in Ukraine. Further, while implementation was successful overall, uptake across regions was uneven. The report concludes by listing a number of policy options to support the sustainability and expansion of the Affordable Medicines Programme.
more
A comprehensive compilation is provided of the medicinal plants of the Southeast Asian country of Myanmar (formerly Burma). This contribution, containing 123 families, 367 genera, and 472 species, was compiled from earlier treatments, monographs, books, and pamphlets, with some medicinal uses and pr...eparations translated from Burmese to English. The entry for each species includes the Latin binomial, author(s), common Myanmar and English names, range, medicinal uses and preparations, and additional notes. Of the 472 species, 63 or 13% of them have been assessed for conservation status and are listed in the IUCN Red List of Threatened Species (IUCN 2017). Two species are listed as Extinct in the Wild, four as Threatened (two Endangered, two Vulnerable), two as Near Threatened, 48 Least Concerned, and seven Data Deficient. Botanic gardens worldwide hold 444 species (94%) within their living collections, while 28 species (6%) are not found any botanic garden. Preserving the traditional knowledge of Myanmar healers contributes to Target 13 of the Global Strategy for Plant Conservation
more
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
First Revised Edition
March 2000